[Basic and clinical aspects of calcimimetics. The clinical effect and usefulness of Cinacalcet as a calcimimetics on three CKD-5D patients undergoing hemodialysis with refractory secondary hyperparathyroidism].

In this part, we reports the experience of treatment by calcimimetics for 3 hemodialyzed patients with refractory secondary hyperparathyroidism. They purchased own expense, and used "Cinacalcet" as calcimimetics (Sensipar(R) 30 mg/tablet, by AMGEN co. Ltd. in USA) . Serum Ca, P, and intact-PTH decreased certainly in 3 cases after cinacalcet therapy. Especially the reduction of intact-PTH is obviously. The any adverse effect did not observed by 30 mg/tablet/day prescription except mild epigastralgia in a case. We were able to experience the marked suppressive effect on parathyroid gland by cinacalcet as calcimimetics in Japanese patients with refractory secondary hyperparathyroidism undergoing hemodialysis.